Why So Shy? – Implementing Disruptive Technologies with Confidence in Cell Therapy
SHARE NOW
Invetech’s Head of Business Development, David Hodl, hosted this Breakfast Briefing at Advanced Therapies Week 2022. Watch as David leads a discussion on how to implement disruptive technologies appropriately into manufacturing processes.
David was joined by panelists: Matthew Li, Associate Director, Head of Cell Therapy Manufacturing Innovation at Vor Biopharma, Fabio Fachin, Head Cell Therapy Process Development, Automation and Digital Technologies at Takeda, and Nicholas Ostrout, Senior Director of Commercial Strategy and Implementation at Lonza.
The panel discussed a key concern faced by companies in the process of commercializing and scaling production: how to bring in new technology. This included considerations for:
- Evaluating how new technology will align with current platforms and development processes
- Best practice for navigating the addition of new technologies to established manufacturing processes
- Optimizing efficiency of manufacturing processes through technology
Highlighting how to assess the potential benefits, risks, and costs of implementing disruptive technologies, the panelists provide suggestions for solutions to this process confidently and effectively.
This briefing has been produced in partnership with Invetech.
Enjoyed this briefing? Join the network to access exclusive content from Advanced Therapies Week 2022 >>
